Advertisement

Is endoscopic ultrasonography more sensitive than magnetic resonance imaging in detecting and localizing pancreatic neuroendocrine tumors?

  • Peter Herbert KannEmail author
Article

Abstract

To compare endoscopic ultrasonography (EUS) and magnetic resonance imaging (MRI) in terms of their sensitivities to localize pancreatic neuroendocrine tumors (pNET) preoperatively. Systematic analysis of the literature; sensitivity of EUS and MRI in insulinomas and pancreaticoduodenal NETs in multiple endocrine neoplasia type 1 (MEN1) in series of at least 20 subjects referring to tumors confirmed by surgery and histopathology. Other imaging methods reported were also assessed. Eighteen publications on insulinomas (782 cases) could be analyzed, no study in MEN1 fulfilled the inclusion criteria and compared EUS to MRI. Data quality was moderate: all publications referred to case series. Mean correct detection / localization rates (sensitivity) were calculated: EUS 80%, MRI 66%, computed tomography 63%, angiography 52%, somatostatin receptor scintigraphy 42%, ultrasonography 23%; arterial calcium stimulation with hepatic venous sampling regionalized correctly in 80%. EUS seems to be more sensitive than MRI in localizing pancreatic neuroendocrine tumors. If a specialized endosonographist is available, EUS is the preferable imaging procedure. Otherwise, MRI is a suitable alternative.

Keywords

Endoscopic ultrasonography EUS Magnetic resonance imaging MRI Neuroendocrine tumor NET Insulinoma 

Abbreviations

ASVS

arterial calcium stimulation with hepatic venous sampling

CT

computed tomography

EUS

endoscopic ultrasonography

MRI

magnetic resonance imaging

NEN

neuroendocrine neoplasia

pNET

pancreatic neuroendocrine tumor(s)

SRS

somatostatin receptor scintigraphy

US

ultrasound

Notes

Compliance with ethical standards

Conflict of interest

The author declares that there is no conflict of interest or whatever conflict there might be perceived.

References

  1. 1.
    Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, et al. Limited value of Ga-68-DOTATOC-PET-CT in routine screening of patients with multiple endocrine neoplasia type 1. World J Surg. 2017;41(6):1521–7.CrossRefGoogle Scholar
  2. 2.
    Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–7.CrossRefGoogle Scholar
  3. 3.
    Chen X, Cai WY, Yang WP, Li HW. Pancreatic insulinomas: diagnosis and surgical treatment of 74 patients. Hepatobiliary Pancreat Dis Int. 2002;1(3):458–61.PubMedGoogle Scholar
  4. 4.
    Druce MR, Muthuppalaniappan VM, O'Leary B, Chew SL, Drake WM, Monson JP, et al. Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol. 2010;162(5):971–8.CrossRefGoogle Scholar
  5. 5.
    Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M. Diagnostik und operative Therapie beim Insulinom - Erfahrungen bei 40 Patienten. Dtsch Med Wochenschr. 2004;129(17):941–6.CrossRefGoogle Scholar
  6. 6.
    Fernández-Cruz L, Blanco L, Cosa R, Rendón H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg. 2008;32(5):904–17.CrossRefGoogle Scholar
  7. 7.
    Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181(4):987–92.CrossRefGoogle Scholar
  8. 8.
    Grygiel K, Szmidt J, Jeleńska M, Pawlak K. Surgical treatment of hyperinsulinism during the course of pancreatic cancer (insulinoma) - one center experience. Pol Przegl Chir. 2012;84(1):31–6.CrossRefGoogle Scholar
  9. 9.
    Jyotsna VP, Pal S, Kandasamy D, Gamanagatti S, Garg PK, Raizada N, et al. Evolving management of insulinoma: experience at a tertiary care centre. Indian J Med Res. 2016;144(5):771.CrossRefGoogle Scholar
  10. 10.
    Kaczirek K, Ba-Ssalamah A, Schima W, Niederle B. The importance of preoperative localisation procedures in organic hyperinsulinism--experience in 67 patients. Wien Klin Wochenschr. 2004;116(11–12):373–8.CrossRefGoogle Scholar
  11. 11.
    Kann PH, Rothmund M, Zielke A. Endoscopic ultrasound imaging of insulinomas: limitations and clinical relevance. Exp Clin Endocrinol Diabetes. 2005;113(8):471–4.CrossRefGoogle Scholar
  12. 12.
    Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose K-J, Behr T, Langer P. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1 (MEN1): An endoscopic ultrasound imaging study. Endocr-relat Cancer. 2006;13:1195–202.Google Scholar
  13. 13.
    Kann PH, Ivan D, Pfützner A, Forst T, Langer P, Schaefer S. Preoperative diagnosis of insulinoma: low body mass index, young age, and female gender are associated with negative imaging by endoscopic ultrasound. Eur J Endocrinol. 2007;157(2):209–13.CrossRefGoogle Scholar
  14. 14.
    Kann PH, Moll R, Bartsch D, Pfützner A, Forst T, Tamagno G, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine. 2017;56(1):158–63.CrossRefGoogle Scholar
  15. 15.
    Lewis MA, Thompson GB, Young WF Jr. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg. 2012;36(6):1375–81.CrossRefGoogle Scholar
  16. 16.
    Machado MC, da Cunha JE, Jukemura J, Bacchella T, Penteado S, Abdo EE, et al. Insulinoma: diagnostic strategies and surgical treatment. A 22-year experience. Hepato-Gastroenterology. 2001;48(39):854–8.PubMedGoogle Scholar
  17. 17.
    Morganstein DL, Lewis DH, Jackson J, Isla A, Lynn J, Devendra D, et al. The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. Eur Radiol. 2009;19(10):2467–73.CrossRefGoogle Scholar
  18. 18.
    Queiroz Almeida M, Machado MC, Correa-Giannella ML, Giannella-Neto D, Albergaria Pereira MA. Endogenous hyperinsulinemic hypoglycemia: diagnostic strategies, predictive features of malignancy and long-term survival. J Endocrinol Investig. 2006;29(8):679–87.CrossRefGoogle Scholar
  19. 19.
    Sotoudehmanesh R, Hedayat A, Shirazian N, Shahraeeni S, Ainechi S, Zeinali F, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31(3):238–41.CrossRefGoogle Scholar
  20. 20.
    Téllez-Ávila FI, Acosta-Villavicencio GY, Chan C, Hernández-Calleros J, Uscanga L, Valdovinos-Andraca F, et al. Diagnostic yield of endoscopic ultrasound in patients with hypoglicemia and insulinoma suspected. Endosc Ultrasound. 2015;4(1):52–5.CrossRefGoogle Scholar
  21. 21.
    Tsang YP, Lang BH, Shek TW. Assessing the short- and long-term outcomes after resection of benign insulinoma. ANZ J Surg. 2016;86(9):706–10.CrossRefGoogle Scholar
  22. 22.
    Varma V, Tariciotti L, Coldham C, Taniere P, Buckels JA, Bramhall SR. Preoperative localisation and surgical management of insulinoma: single centre experience. Dig Surg. 2011;28(1):63–73.CrossRefGoogle Scholar
  23. 23.
    Wei J, Liu X, Wu J, Xu W, Gao W, Jiang K, et al. Diagnosis and surgical management of insulinomas in 33 consecutive patients at a single institution. Langenbeck's Arch Surg. 2016;401(7):1019–25.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centre for Endocrinology, Diabetology & Osteology, Endocrine LaboratoryPhilipp‘s University and University Hospital MarburgMarburgGermany
  2. 2.German Centre for Endocrine CareFrankfurt / MainGermany

Personalised recommendations